Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
14(78%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
14
78%
Ph phase_1
3
17%
Ph phase_2
1
6%

Phase Distribution

3

Early Stage

1

Mid Stage

14

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
3(16.7%)
Phase 2Efficacy & side effects
1(5.6%)
Phase 3Large-scale testing
14(77.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

14

trials recruiting

Total Trials

18

all time

Status Distribution
Active(14)
Completed(4)

Detailed Status

Active, not recruiting10
Completed4
Recruiting4

Development Timeline

Analytics

Development Status

Total Trials
18
Active
14
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (16.7%)
Phase 21 (5.6%)
Phase 314 (77.8%)

Trials by Status

completed422%
recruiting422%
active_not_recruiting1056%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT07357415Phase 3

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Recruiting
NCT06383390Phase 3

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Active Not Recruiting
NCT07035093Phase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Recruiting
NCT07165028Phase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Recruiting
NCT07232719Phase 3

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Active Not Recruiting
NCT05929079Phase 3

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active Not Recruiting
NCT06260722Phase 3

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Active Not Recruiting
NCT06662383Phase 3

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Active Not Recruiting
NCT06354660Phase 3

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Completed
NCT06982859Phase 1

A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

Recruiting
NCT06859268Phase 3

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Active Not Recruiting
NCT05931367Phase 3

A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Completed
NCT06982846Phase 1

A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

Active Not Recruiting
NCT06297603Phase 3

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Active Not Recruiting
NCT05936151Phase 2

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Completed
NCT05882045Phase 3

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active Not Recruiting
NCT06808802Phase 1

To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants

Completed
NCT05929066Phase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active Not Recruiting

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18